A Study of XmAb®18087 in Subjects With NET and GIST



Status:Recruiting
Conditions:Cancer, Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:12 - Any
Updated:3/27/2019
Start Date:January 22, 2018
End Date:June 2021
Contact:Barbara Hickingbottom, MD
Email:bhickingbottom@xencor.com
Phone:858-480-3413

Use our guide to learn which trials are right for you!

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)

This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and
regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to
describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily
assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST.

The study will enroll dosing cohorts to establish a MTD/RD and regimen in subjects with
advanced NET or GIST, then enroll additional subjects into separate NET and GIST expansion
cohorts to collect additional data on safety and potential efficacy of XmAb18087.


Inclusion Criteria:

- Histologically or cytologically confirmed well differentiated low or intermediate
grade (World Health Organization [WHO] Grade 1 or 2) NET of pancreatic,
gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic
and has progressed within the past 12 months

- Histologically confirmed GIST that is locally advanced or metastatic

- NET and GIST tumors must be unresectable

- NET subjects must have progressed on or been ineligible for treatment with
somatostatin analogues (SSA) and at least one other FDA-approved targeted therapy
(everolimus or sunitinib).

- GIST subjects must have previously received all FDA-approved therapies (imatinib
mesylate, sunitinib malate, and regorafenib) for which they are eligible

- Must have disease measurable by RECIST 1.1 criteria using either computed tomography
(CT) or magnetic resonance imaging (MRI) scan

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

- Diagnosis of high-grade (WHO Grade 3) or poorly differentiated NET; high-grade
neuroendocrine carcinoma; large cell neuroendocrine carcinoma, small cell carcinoma,
or mixed small and large cell carcinoma.

- Subjects currently receiving anti-cancer therapies (other than SSAs, which may
continue).

- Subjects who have received anti-cancer therapies within 2 weeks of the start of study
drug (including chemotherapy, radiation therapy, immunotherapy, etc.).

- Must not be experiencing a Grade 3 or 4 toxicity from previous anti-cancer treatment

- Must not be receiving other anti-cancer therapies (except somatostatin analogues,
which may be allowed)

- Must not have poorly controlled diabetes mellitus, known central nervous system
involvement by malignant disease or insufficient bone marrow, renal, or hepatic
function
We found this trial at
15
sites
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Phone: 404-778-2670
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
13001 E 17th Pl
Aurora, Colorado 80045
(303) 724-5000
University of Colorado Anschutz Medical Campus Located in the Denver metro area near the Rocky...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Columbus, Ohio 43210
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Duarte, California 91010
Phone: 626-218-0572
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
5777 East Mayo Boulevard
Phoenix, Arizona 85054
(480) 515-6296
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials